• Login
    View Item 
    •   JScholarship Home
    • Theses and Dissertations, Electronic (ETDs)
    • ETD -- Doctoral Dissertations
    • View Item
    •   JScholarship Home
    • Theses and Dissertations, Electronic (ETDs)
    • ETD -- Doctoral Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Mathematical modeling to guide programmatic decisions about the use of new tuberculosis drugs, regimens, and diagnostics

    Thumbnail
    View/Open
    KENDALL-DISSERTATION-2018.pdf (6.327Mb)
    Date
    2018-06-14
    Author
    Kendall, Emily A
    0000-0002-0083-422X
    Metadata
    Show full item record
    Abstract
    Statement of the Problem: Approximately ten million people develop tuberculosis (TB) each year, and this global incidence is declining at a rate of only 2% annually. New diagnostic assays and treatment regimens could improve TB control in high-burden settings, but decisions about whether and how to use these tools often involve multiple competing considerations. For example, the new Xpert MTB/RIF Ultra assay improves sensitivity for TB diagnosis but at the cost of lower specificity. New TB treatment regimens that shorten treatment duration too aggressively could reduce treatment efficacy. A shorter regimen for multidrug-resistant (MDR) TB may increase treatment access, but the non-inferiority of its treatment efficacy remains uncertain. Given such trade-offs, international and country-level decision-makers need to anticipate how new tools are likely to affect various local patient populations and epidemics. Methods: In this dissertation, dynamic transmission models of TB epidemics are used to (1) project the impact on MDR-TB incidence in Southeast Asia of a new 9-month treatment regimen, and (2) to compare the dependence of novel regimens’ impact on regimen characteristics such as efficacy, duration, tolerability, and barrier to resistance. In addition, a Markov model is used to simulate clinical outcomes (unnecessary treatments, deaths averted) of adopting the Xpert MTB/RIF Ultra cartridge, in several hypothetical settings emblematic of global TB epidemiology and in a specific study community in urban Uganda. Results: The 9-month MDR-TB regimen could lower MDR-TB incidence by 23% (95% uncertainty range 10–38%), but this projection depended on raising both treatment effectiveness and treatment availability and on limiting detrimental effects of second-line drug resistance. For novel regimens for both rifampin-susceptible and rifampin-resistant TB, treatment efficacy was the most critical of the regimen characteristics modeled and was responsible for approximately half of a regimen’s maximal epidemiologic impact. The clinical impact of switching to the Xpert MTB/RIF Ultra cartridge varied widely between settings but was most favorable in clinical contexts with high prevalence of both TB and HIV, such as in sub-Saharan Africa. Conclusions: These mathematical models provide useful, context-specific guidance for deciding whether and how to implement new TB treatment regimens or diagnostic tools.
    URI
    http://jhir.library.jhu.edu/handle/1774.2/61101
    Collections
    • ETD -- Doctoral Dissertations

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of JScholarshipCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV